Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > $20.35 cad share price - 1B market cap

<< Previous

Bullboard Posts

Next >>

Post by 2019champson Jul 28, 2021 11:52pm

137 Views

Post# 33619399

$20.35 cad share price - 1B market cap

With todays share structure, a 1B usd market cap puts us at $20.35 cad a share. Can we hit 1B market cap? Let's see. Based on my research, metablok/ cilastatin pipeline can potentially be used for the following: Sepsis, Cancer metastasis, colorectal carcinoma, acute lymphoid leukemia, inflammation as a result of covid19, etc. Keep in mind, the drug targets inflammation in the lung, liver, kidney. I think 1-2B is do-able and maybe even more depending on other upcoming drugs in the pipeline.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand